Moderna Announces Update on Investigational Pandemic Influenza Program
Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines
CAMBRIDGE, MA / ACCESS Newswire Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. The interim results focus on a vaccine candidate targeting the H5 avian influenza virus subtype.
The Company had previously expected to advance the program to late-stage development with the U.S. Department of Health and Human Services (HHS); however, today Moderna received notice that HHS will terminate the award for the late-stage development and right to purchase pre-pandemic influenza vaccines.
'While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats.'
The Phase 1/2 study evaluated a two-dose regimen of Moderna's investigational avian influenza vaccine. mRNA-1018 demonstrated a rapid, potent and durable immune response. At baseline, pre-existing immunity was minimal, with only 2.1% of participants showing hemagglutination inhibition (HAI) antibody titers ≥1:40, an HAI titer considered to correlate with protection. At Day 43, three weeks after the second vaccination, 97.8% of participants achieved titers ≥1:40 with a 44.5-fold increase of titers from baseline.
The investigational vaccine was generally well-tolerated, with no dose-limiting tolerability concerns observed. Most solicited adverse reactions were Grade 1 or 2 and did not increase significantly with number of doses or between first and second doses. Further data is expected to be submitted for presentation at an upcoming scientific meeting.
Moderna will explore alternatives for late-stage development and manufacturing of the H5 program consistent with the Company's strategic commitment to pandemic preparedness.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the clinical development of mRNA-1018, the safety and immunogenicity data from the Phase 1/2 study; the cancellation of the development contract for Moderna's pandemic flu program by the U.S. Department of Health and Human Services; and the exploration of alternative paths for development of the vaccine program. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
26 minutes ago
Draft of new 'MAHA' report suggests RFK Jr. won't target pesticides
The draft of an upcoming government report suggesting ways to improve the health of American children does not recommend severe restrictions on pesticides and ultra-processed foods, according to a copy of the document obtained by ABC News. The draft's language, if left unchanged, would constitute a win for the agriculture industry and a potential setback for Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. and his "Make America Healthy Again" (MAHA) allies, who have railed against the use of chemical additives in America's food supply, arguing that they harm children. A person familiar with the draft cautioned that the language could still change before it's released to the public. "Unless officially released by the administration, any document purporting to be the MAHA report should be dismissed as speculative literature," White House deputy press secretary Kush Desai said in response to ABC News' request for comment. An HHS spokesperson declined to verify the document's authenticity. The New York Times first reported details of the new draft report. The report will be the second "MAHA" report released by the Trump administration following one published in May. Both were composed by officials in the White House and across different federal agencies, including Kennedy's HHS. The May report detailed the factors officials said were worsening the health of American children and called for a second report, within 100 days, to recommend policies to address those factors. The earlier report -- which was dogged by the revelation that some studies it cited were nonexistent -- cited damning statistics about the effect of chemical food additives, tying them to cancer and developmental disorders. The draft of the new report does not signal any intention to eliminate pesticides from America's food. Instead, the draft calls for "more targeted and precise pesticide applications" and research programs that would "help to decrease pesticide volumes." The report also stated the Environmental Protection Agency "will work to ensure that the public has awareness and confidence in EPA's robust pesticide review procedures and how that relates to the limiting of risk for users and the general public." Regarding ultra-processed foods, the new report states only that HHS, the U.S. Department of Agriculture and the Food and Drug Administration would work to develop a "government-wide definition for 'ultra-processed food.'" In his January confirmation hearing, Kennedy declared that "something is poisoning the American people, and we know that the primary culprits are changing food supply, a switch to highly chemical intensive processed foods." Meanwhile, some "MAHA" influencers have loudly demanded changes to the country's food supply, putting their faith in Kennedy to leverage his position of power to uproot the agriculture industry. But this summer, agriculture groups lobbied intensely against the inclusion of anti-pesticide recommendations in the new report. They appeared to find an ally in Secretary of Agriculture Brooke Rollins, who indicated to reporters this month that the upcoming report would spare pesticides. "There is no chance that our current system of agriculture can survive without those crop protection tools," she said at a press conference in a Washington. "I feel very confident that his, and our, commitment to make sure that farmers are at the table remains paramount, and that the report will reflect that."
Yahoo
an hour ago
- Yahoo
If You're in Your 30s, Consider Buying These 2 Healthcare Stocks
Key Points Intuitive Surgical leads the robotic-assisted surgery market and benefits from long-term trends. Moderna is an innovative vaccine maker which saw success in the pandemic and has a deep pipeline. Both stocks could help investors in their 30s achieve substantial returns over the long term. 10 stocks we like better than Intuitive Surgical › Investing styles tend to evolve as people age. Seniors who are already retired often look for steady, reliable, dividend-paying companies. Younger investors, on the other hand, can afford to take more risks and tend to seek out companies that, despite being more volatile, also boast significant long-term upside potential. With that in mind, let's consider two stocks that people in their 30s -- who are still a good distance away from retirement -- should consider investing in: Intuitive Surgical (NASDAQ: ISRG) and Moderna (NASDAQ: MRNA). 1. Intuitive Surgical Intuitive Surgical is a medical specialist that leads the market for robotic-assisted surgery (RAS) devices, thanks to its famous da Vinci system, which is by far its most important growth driver. This machine enables physicians to perform minimally invasive surgeries across a range of approved indications, including bariatric, urologic, and general surgery. The company has faced several challenges over the past few years, including a decline in bariatric surgeries due to the growing popularity of anti-obesity medications, and the threat posed by the Trump administration's tariffs. Despite those problems, its long-term prospects look incredibly attractive. One reason is that Intuitive Surgical has a resilient business. The company has achieved excellent results over the past five years, with consistently growing top- and bottom-line numbers: Another great reason to remain bullish on the company's long-term prospects is that its addressable market still looks underpenetrated. Intuitive Surgical makes more than half of its revenue from sales of instruments and accessories, which are tied to procedure volume. The more surgeries physicians perform with its devices, the higher its sales. Thus, Intuitive Surgical will benefit from demographic changes that are happening right under our noses, as the world's population ages. By the time investors in their 30s retire, a much higher proportion of the population will be seniors who are in greater need of the kinds of procedures Intuitive Surgical offers. Furthermore, even with mounting competition, the company benefits from a wide moat due to switching costs (da Vinci systems are expensive) and intangible assets, namely patents that protect its inventions. Intuitive Surgical has consistently outperformed the market over the past 25 years, and it's likely to continue doing so, helping younger investors significantly grow their capital over time. 2. Moderna Moderna is a riskier bet than Intuitive Surgical, but the biotech also has significant upside potential. The vaccine maker demonstrated its innovative capabilities by developing one of the most successful COVID-19 vaccines on the market. Several pharmaceutical leaders tried and failed, but Moderna succeeded; that's saying something. The company's mRNA platform is attractive because vaccines based on it tend to be faster and cheaper to develop. And since its success in the coronavirus space, Moderna has recorded several clinical and regulatory wins. It earned approval for a vaccine for respiratory syncytial virus (RSV) and recorded phase 2 or phase 3 wins for vaccines against influenza, influenza plus COVID, and even cancer. Why, then, has the stock significantly lagged the market over the past three years? Moderna's coronavirus vaccine franchise is no longer generating the sales and profits it once did. The company's shares probably rose too much too fast in the early pandemic years, meaning a sell-off was justified. However, now Moderna could take off and deliver superior returns over the long run, provided it continues to innovate. To that end, the company's pipeline looks attractive, with potential candidates across even ambitious targets. Moderna's personalized cancer vaccine, mRNA-4157, which helped decrease the risk of recurrence and death in melanoma patients in phase 2 studies, is now in late-stage clinical trials. The company is targeting many other cancers, and is even working on a potential HIV vaccine that's in early-stage clinical trials. While mRNA vaccines are still relatively new to the market, if Moderna manages to make them mainstream by launching several over the next five years, there could be a massive upside for the stock. Again, it's a riskier bet, but investors in their 30s who can handle the volatility should seriously consider Moderna. Should you buy stock in Intuitive Surgical right now? Before you buy stock in Intuitive Surgical, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Intuitive Surgical wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Intuitive Surgical. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy. If You're in Your 30s, Consider Buying These 2 Healthcare Stocks was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
GoHealth Second Quarter 2025 Earnings: Misses Expectations
Explore GoHealth's Fair Values from the Community and select yours GoHealth (NASDAQ:GOCO) Second Quarter 2025 Results Key Financial Results Revenue: US$94.0m (down 11% from 2Q 2024). Net loss: US$55.2m (loss widened by 105% from 2Q 2024). US$5.10 loss per share (further deteriorated from US$2.70 loss in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period GoHealth Revenues and Earnings Miss Expectations Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 100%. Looking ahead, revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Insurance industry in the US. Performance of the American Insurance industry. The company's share price is broadly unchanged from a week ago. Risk Analysis What about risks? Every company has them, and we've spotted 3 warning signs for GoHealth you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
